Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis

Inclusion Criteria: 1. Male and female adults 19 years of age or older at the time of screening visit 2. A person who is scheduled to administer the research drug according to the medical judgment of the researcher based on the permission 3. A person who can understand the information provided to the person and can voluntarily sign a written consent form Exclusion Criteria: 1. Those subject to contraindications to administration according to the drug approval requirements for research * Patients with hypersensitivity to the components of this drug or other bisphosphonate drugs Hypocalcemia * Patients with severe renal impairment whose creatinine clearance rate is less than 35 mL/min (patients must measure serum creatinine and creatinine clearance before receiving the study drug). * Patients receiving Zometa for cancer as an indication * Pregnant women, women who may be pregnant, and lactating women 2. Patients participating in other clinical trials (However, registration is possible if you have not received investigational drugs or are participating in other non-interventional observational studies.) 3. In addition to the above, patients whom the researcher (physician in charge) determines are not suitable as subjects of this observational study.